203 related articles for article (PubMed ID: 30563932)
1. PRE-surgical Metformin In Uterine Malignancy (PREMIUM): a Multi-Center, Randomized Double-Blind, Placebo-Controlled Phase III Trial.
Kitson SJ; Maskell Z; Sivalingam VN; Allen JL; Ali S; Burns S; Gilmour K; Latheef R; Slade RJ; Pemberton PW; Shaw J; Ryder WD; Kitchener HC; Crosbie EJ
Clin Cancer Res; 2019 Apr; 25(8):2424-2432. PubMed ID: 30563932
[TBL] [Abstract][Full Text] [Related]
2. Measuring the biological effect of presurgical metformin treatment in endometrial cancer.
Sivalingam VN; Kitson S; McVey R; Roberts C; Pemberton P; Gilmour K; Ali S; Renehan AG; Kitchener HC; Crosbie EJ
Br J Cancer; 2016 Feb; 114(3):281-9. PubMed ID: 26794276
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study.
Soliman PT; Zhang Q; Broaddus RR; Westin SN; Iglesias D; Munsell MF; Schmandt R; Yates M; Ramondetta L; Lu KH
Gynecol Oncol; 2016 Dec; 143(3):466-471. PubMed ID: 27745917
[TBL] [Abstract][Full Text] [Related]
4. Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer.
Schuler KM; Rambally BS; DiFurio MJ; Sampey BP; Gehrig PA; Makowski L; Bae-Jump VL
Cancer Med; 2015 Feb; 4(2):161-73. PubMed ID: 25417601
[TBL] [Abstract][Full Text] [Related]
5. Metformin is associated with reduced cell proliferation in human endometrial cancer by inbibiting PI3K/AKT/mTOR signaling.
Zhao Y; Sun H; Feng M; Zhao J; Zhao X; Wan Q; Cai D
Gynecol Endocrinol; 2018 May; 34(5):428-432. PubMed ID: 29182407
[TBL] [Abstract][Full Text] [Related]
6. Effect of Metformin For Decreasing Proliferative Marker in Women with Endometrial Cancer: A Randomized Double-blind Placebo-Controlled Trial.
Petchsila K; Prueksaritanond N; Insin P; Yanaranop M; Chotikawichean N
Asian Pac J Cancer Prev; 2020 Mar; 21(3):733-741. PubMed ID: 32212801
[TBL] [Abstract][Full Text] [Related]
7. A presurgical window-of-opportunity study of metformin in obesity-driven endometrial cancer.
Sivalingam V; McVey R; Gilmour K; Ali S; Roberts C; Renehan A; Kitchener H; Crosbie E
Lancet; 2015 Feb; 385 Suppl 1():S90. PubMed ID: 26312913
[TBL] [Abstract][Full Text] [Related]
8. Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial.
Mitsuhashi A; Kiyokawa T; Sato Y; Shozu M
Cancer; 2014 Oct; 120(19):2986-95. PubMed ID: 24917306
[TBL] [Abstract][Full Text] [Related]
9. Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer.
Laskov I; Drudi L; Beauchamp MC; Yasmeen A; Ferenczy A; Pollak M; Gotlieb WH
Gynecol Oncol; 2014 Sep; 134(3):607-14. PubMed ID: 24972190
[TBL] [Abstract][Full Text] [Related]
10. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multi-center randomized controlled trial.
Feig DS; Murphy K; Asztalos E; Tomlinson G; Sanchez J; Zinman B; Ohlsson A; Ryan EA; Fantus IG; Armson AB; Lipscombe LL; Barrett JF;
BMC Pregnancy Childbirth; 2016 Jul; 16(1):173. PubMed ID: 27435163
[TBL] [Abstract][Full Text] [Related]
11. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.
Bonanni B; Puntoni M; Cazzaniga M; Pruneri G; Serrano D; Guerrieri-Gonzaga A; Gennari A; Trabacca MS; Galimberti V; Veronesi P; Johansson H; Aristarco V; Bassi F; Luini A; Lazzeroni M; Varricchio C; Viale G; Bruzzi P; Decensi A
J Clin Oncol; 2012 Jul; 30(21):2593-600. PubMed ID: 22564993
[TBL] [Abstract][Full Text] [Related]
12. Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.
Pusceddu S; de Braud F; Concas L; Bregant C; Leuzzi L; Formisano B; Buzzoni R
Tumori; 2014; 100(6):e286-9. PubMed ID: 25688512
[TBL] [Abstract][Full Text] [Related]
13. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy.
Barnett AH; Charbonnel B; Li J; Donovan M; Fleming D; Iqbal N
Clin Drug Investig; 2013 Oct; 33(10):707-17. PubMed ID: 23949898
[TBL] [Abstract][Full Text] [Related]
14. Jupiter microtubule-associated homolog 1 (JPT1): A predictive and pharmacodynamic biomarker of metformin response in endometrial cancers.
Bateman NW; Teng PN; Hope E; Hood BL; Oliver J; Ao W; Zhou M; Wang G; Tommarello D; Wilson K; Litzy T; Conrads KA; Hamilton CA; Darcy KM; Casablanca Y; Maxwell GL; Bae-Jump V; Conrads TP
Cancer Med; 2020 Feb; 9(3):1092-1103. PubMed ID: 31808620
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial.
van der Aa MP; Elst MA; van de Garde EM; van Mil EG; Knibbe CA; van der Vorst MM
Nutr Diabetes; 2016 Aug; 6(8):e228. PubMed ID: 27571249
[TBL] [Abstract][Full Text] [Related]
16. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.
De Jager J; Kooy A; Lehert P; Bets D; Wulffelé MG; Teerlink T; Scheffer PG; Schalkwijk CG; Donker AJ; Stehouwer CD
J Intern Med; 2005 Jan; 257(1):100-9. PubMed ID: 15606381
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia and hyperglycaemia determine why some endometrial tumours fail to respond to metformin.
Sivalingam VN; Latif A; Kitson S; McVey R; Finegan KG; Marshall K; Lisanti MP; Sotgia F; Stratford IJ; Crosbie EJ
Br J Cancer; 2020 Jan; 122(1):62-71. PubMed ID: 31819173
[TBL] [Abstract][Full Text] [Related]
18. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F
Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683
[TBL] [Abstract][Full Text] [Related]
19. Metformin does not reduce markers of cell proliferation in esophageal tissues of patients with Barrett's esophagus.
Chak A; Buttar NS; Foster NR; Seisler DK; Marcon NE; Schoen R; Cruz-Correa MR; Falk GW; Sharma P; Hur C; Katzka DA; Rodriguez LM; Richmond E; Sharma AN; Smyrk TC; Mandrekar SJ; Limburg PJ;
Clin Gastroenterol Hepatol; 2015 Apr; 13(4):665-72.e1-4. PubMed ID: 25218668
[TBL] [Abstract][Full Text] [Related]
20. The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients.
Petrera M; Paleari L; Clavarezza M; Puntoni M; Caviglia S; Briata IM; Oppezzi M; Mislej EM; Stabuc B; Gnant M; Bachleitner-Hofmann T; Roth W; Scherer D; Haefeli WE; Ulrich CM; DeCensi A
BMC Cancer; 2018 Dec; 18(1):1210. PubMed ID: 30514262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]